comparemela.com

Latest Breaking News On - Ankylosing spondylitis bechterews disease - Page 1 : comparemela.com

FDA Approves Secukinumab for Adults With HS

This marks the second FDA-approved agent for the condition, and the first IL-17A inhibitor.

San franciscoUnited statesPp haley naikSecukinumab cosentyxDrug administrationUniversity of californiaHidradenitis suppurativa clinical responseHidradenitis suppurativaPlaque psoriasisPsoriatic arthritisAnkylosing spondylitis bechterews diseaseSkin and soft tissue infectionUs food and drug administrationNited states food and drug administrationClinical researchClinical trials

FDA Approves Bimekizumab for Plaque Psoriasis in Adults

Bimekizumab is the first IL-17A and IL-17F inhibitor approved by the FDA for adults with psoriasis.

New yorkUnited statesMark lebwohlEuropean unionIcahn school of medicine at mount sinaiNational psoriasis foundationDrug administrationNational psoriasisIcahn schoolMount sinaiNew york cityPsoriasis areaSeverity indexGlobal assessmentPsoriatic arthritisPlaque psoriasis

FDA Approves Intravenous Formulation of Secukinumab

This new route of administration is expected to become available during the fourth quarter of 2023.

Philipj measeChristy siegelUniversity of washingtonSchool of medicineDrug administrationSwedish medical centerPsoriatic arthritisIntravenous ivAnkylosing spondylitisBiologic therapyOint inflammationTnf alphaTumor necrosis factor alphaUmor necrosis factor tnfHealthcare and medical technologyEalth and medical tech

FDA OKs Ninth Humira Biosimilar, With Interchangeability

The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available later this month.

United statesUniversity of texas southwestern medical centerRoy fleischmannDrug administrationTexas southwestern medical centerRheumatoid arthritisBiologic therapyBiosimilar drugsFollow on biologicsPsoriatic arthritisHidradenitis suppurativaUlcerative colitisAnkylosing spondylitisCrohns diseaseAnkylosing spondylitis bechterews diseaseAxial spondyloarthritis axspa

CV Disease, Drug Abuse Big Contributors to Mortality in AS

Congestive heart failure and renal disease were the strongest contributing comorbidities to mortality in hospitalized patients with ankylosing spondylitis.

Eli lillyMohamad bittarCerner health facts databaseUniversity of tennessee health science centerCerner health factsTennessee health science centerAnkylosing spondylitisHeart failureAnkylosing spondylitis bechterews diseaseRenal diseaseKidney diseaseKidney disorderRenal disorderDrug abuseCongestive heart failureRespiratory failure

vimarsana © 2020. All Rights Reserved.